Evidence map›Paper›PMID 41321747›Full record

ArticleEJHaem2025

Baseline Cytomegalovirus Immunoglobulin G Levels Predict Reactivation in Patients With Multiple Myeloma Receiving Elranatamab.

Ukyo Kondo, Taku Kikuchi, Shotaro Sugita, Miyu Watanabe, Chiaki Matsumoto, Moe Nomura-Yogo, Kodai Kunisada, Kota Sato, Tomomi Takei, Mizuki Ogura and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJHaem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ukyo KondoDepartment of Hematology Japanese Red Cross Medical Center Shibuya Tokyo Japan.
Taku KikuchiDepartment of Hematology Japanese Red Cross Medical Center Shibuya Tokyo Japan.ORCID https://orcid.org/0000-0002-3210-7756
Shotaro SugitaDepartment of Hematology Japanese Red Cross Medical Center Shibuya Tokyo Japan.
Miyu WatanabeDepartment of Hematology Japanese Red Cross Medical Center Shibuya Tokyo Japan.
Chiaki MatsumotoDepartment of Pharmacy Japanese Red Cross Medical Center Shibuya Tokyo Japan.
Moe Nomura-YogoDepartment of Hematology Japanese Red Cross Medical Center Shibuya Tokyo Japan.
Kodai KunisadaDepartment of Hematology Japanese Red Cross Medical Center Shibuya Tokyo Japan.
Kota SatoDepartment of Hematology Japanese Red Cross Medical Center Shibuya Tokyo Japan.
Tomomi TakeiDepartment of Hematology Japanese Red Cross Medical Center Shibuya Tokyo Japan.
Mizuki OguraDepartment of Hematology Japanese Red Cross Medical Center Shibuya Tokyo Japan.
Yu AbeDepartment of Hematology Japanese Red Cross Medical Center Shibuya Tokyo Japan.
Osamu HosoyaDepartment of Pharmacy Japanese Red Cross Medical Center Shibuya Tokyo Japan.
Tadao IshidaDepartment of Hematology Japanese Red Cross Medical Center Shibuya Tokyo Japan.
Nobuhiro TsukadaDepartment of Hematology Japanese Red Cross Medical Center Shibuya Tokyo Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The cumulative incidence and risk of cytomegalovirus (CMV) reactivation in patients with relapsed/refractory multiple myeloma (RRMM) receiving elranatamab remain unclear. Methods: We retrospectively analyzed RRMM patients treated with elranatamab to assess cumulative incidence and risk factors for CMV reactivation. Results: Among 32 patients, the 6-month cumulative incidence of CMV reactivation was 37.3%. High CMV immunoglobulin G (IgG) titers were significantly associated with CMV reactivation (57.9% vs. 9.1%, Conclusion: Baseline CMV IgG titers may help guide risk-adapted monitoring and prevention strategies during elranatamab therapy.

Indexed as

CMV IgGcytomegaloviruselranatamabmultiple myeloma

Identifiers

PMID41321747
PMCPMC12661365

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.